Clinical Research | Medical XPRT
Articles & Whitepapers
-
Comparison and Analysis of SMDC, ADC, and DAC
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the therapeutic index while providing selective delivery. What are their similarities and differences? What are their respective advantages? What is the current status of ...
-
RNA-targeted Gene Therapy
In recent years, various nucleic acid-based therapies (NBT) have emerged as effective and specific activators of endogenous gene expression. Unlike gene therapy approaches supplementing gene ...
News
-
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the ...
VisionQuest Abstract on Diabetic Peripheral Neuropathy Accepted by ADA
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
Atmo Biosciences awarded Australian Government grant to automate and scale-up manufacturing of ingestible gas-sensing capsule
Equipment & Solutions
-
Showcase
Pharmacy Refrigerator
It is suitable for pharmacies, pharmaceutical factories, hospitals, clinics, scientific research institutes, centers for disease prevention and control and other industrial institutions, used to store medicines, reagents, vaccines, biological products, etc.
Upcoming Events
-
Showcase
IVDR: our next Challenge?
In practice: The agenda will be built considering case studies and (project/regulatory) experience from the EBF community and presentations from a call for abstract (deadline for abstract submission: 15 March 2024). Meeting attendance will be limited to 60 delegates with a maximum of 3 delegates/company.